Fecal microbiota transplants (FMTs), once hailed as a potential panacea for a wide range of ailments, from inflammatory bowel diseases, obesity, and type 2 diabetes to autism, are now facing growing concerns over their safety. New research conducted by scientists at the University of Chicago has sounded a cautionary note, indicating that the widespread use of FMTs could lead to long – lasting, unintended health consequences for recipients.
The study, published in the prestigious journal Cell, involved experiments on mice and analyses of human tissue samples. The researchers discovered that anaerobic microbes from the colon, when transplanted, did not merely stay in their intended location. Instead, they successfully colonized the small bowel after a single transplant and persisted there for months. These invading microbes then proceeded to reshape their new intestinal environments to their own advantage. In a process akin to “terraforming,” they induced changes in the recipient’s metabolism, behavior, and energy balance. Orlando (Landon) DeLeon, PhD, a postdoctoral researcher at UChicago and the lead author of the study, emphasized, “This finding serves as a wake – up call for the field. We can’t casually introduce large bowel microbes into other parts of the intestine where they don’t naturally belong.” He further noted that when designing therapeutic strategies, it is crucial to ensure that the regional microbiota is appropriately matched to its environment, as this is key to delivering overall health benefits. The study’s conclusion, as stated in its title “Microbiome mismatches from microbiota transplants lead to persistent off – target metabolic and immunomodulatory effects,” clearly points out that regional microbial mismatches after FMTs can result in unforeseen consequences and calls for a reevaluation of microbiome – based interventions.
FMT involves the transfer of stool – derived microbes from a healthy individual to a patient, with the aim of restoring a healthy balance in the recipient’s gut microbiome. While the U.S. Food and Drug Administration (FDA) has only approved FMT for treating recurrent Clostridium difficile (C. diff) infections, a practice that has shown significant success, many physicians have been eager to explore its application in treating other digestive and systemic conditions. However, as the new research highlights, the gut is a complex ecosystem composed of several distinct regions, each with its own unique microbial community tailored to perform specific functions essential for the host’s health. Since stool primarily contains anaerobic microbes from the colon, FMT can disrupt the delicate balance of the gut ecosystem when these bacteria colonize the small intestine and other areas of the digestive system. The researchers question the suitability of FMT, especially in restoring the microbiota in the small bowel, due to its predominantly anaerobic composition. DeLeon raised a valid concern, stating, “The entire intestinal tract harbors diverse microbes, yet we mainly focus on the colon, which is just the last third of it. So, how can we expect FMT, using microbes from only one – third of the intestinal tract, to effectively restore the health of the entire intestine?”
In their experiments, DeLeon and his team, including senior author Eugene B. Chang, MD, the Martin Boyer Professor of Medicine at UChicago, administered FMTs to antibiotic – treated mice. They compared the effects of transplants from different sources: the jejunum (the first part of the small intestine), the cecum (a section connecting the small and large intestines with a mixed microbial population), and standard fecal microbiota. The results were striking. Microbes from all transplant sources managed to colonize the entire intestinal tract of the mice, not just their native habitats, creating persistent regional gut mismatches that lasted up to three months after a single transplant. Moreover, these altered microbiomes led to changes in the production of metabolites in each intestinal region, which in turn affected the host’s liver metabolism and other physiological processes.
These findings not only challenge the current enthusiasm for FMT but also underscore the need for more rigorous research into its safety and efficacy. As the medical community continues to explore the potential of FMTs, it is essential to carefully consider the risks associated with microbiome mismatches and develop strategies to mitigate them. Only through a better understanding of the complex interactions within the gut microbiome can we hope to harness the true therapeutic potential of FMTs while safeguarding the health of patients.
Related topics：
